Advancing new potential treatments for certain GI diseases affecting millions of patients in need

  • Compound
  • Indication
  • Approval
  • Linzess® Partner
  • IBS-C or CIC in adults

  • Launched 12/12; sNDA for overall abdominal symptoms submitted Nov 2019
  • linaclotide Partner
  • IBS-C/FC in pediatrics

  • MD-7246 Partner
  • Abdominal pain associated with IBS-D

  • Phase II trial results targeted mid-2020

Status of selected key development programs as of February 25, 2020. Represents ongoing phase of development; does not correspond to completion of a particular phase.

Click here for LINZESS® full US Prescribing Information including BOXED WARNING.

Copyright © 2020, Ironwood Pharmaceuticals, Inc. All Rights Reserved

LINZESS®, CONSTELLA®, IRONWOOD® and their associated logos are trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to herein are the property of their respective owners. All rights reserved.